Michael P. Bevilacqua, M.D., Ph.D., Chief Executive Officer and Chief Scientific Officer
Dr. Bevilacqua, co-founder of Amicrobe, brings more than 30 years of experience as a medical scientist, inventor, and business executive. He has led successful research laboratories at Harvard Medical School and as a Howard Hughes investigator at UCSD Medical Center. As VP of Amgen, he built a division for inflammatory and immunological diseases. Dr. Bevilacqua has founded and / or worked with start-up corporations in both therapeutics and diagnostics. His scientific work has led to many patents and publications.
Timothy J. Deming, Ph.D., Consultant
Prof. Deming is a key consultant and co-founder. He has pioneered novel methods for the controlled synthesis of copolypeptides, publishing more than 70 articles and 16 patents. Professor Deming's research utilizes innovative chemistry techniques to synthesize and characterize complex biomaterials based on copolypeptides. He has led successful research programs at UCSB and served as Chair of the UCLA Bioengineering Department, where he is currently a professor.
Carl K. Edwards, III, Ph.D., Director of Preclinical Development
Dr. Edwards has over 20 years R&D experience in leading corporations (Amgen, Marion Merrell Dow, Schering AG, Western States Biopharmaceuticals). At Amgen, he was Clinical Research Project Team Leader for more than five products (two approved by the FDA). At Amicrobe, Dr. Edwards is responsible for designing and executing the development programs to enter first-in-man studies.
Brian D. Wall, Ph.D., Laboratory Head, Materials Science
Dr. Wall is a polymer chemist with expertise in materials chemistry and stimuli-responsive materials. He obtained his Ph.D. in Chemistry at Johns Hopkins University where he studied self-assembling peptides. At Amicrobe, he is responsible for advanced biomaterials R&D, including A-Blocksanalytics and product engineering.
Daniel J. Huang, Director of Operations
Mr. Huang oversees internal operations, as well as outside interactions with contract research / manufacturing organizations. He also contributes substantially to R&D project management and business development efforts. Mr. Huang's education and work experience in molecular biology (Occidental College) and data management serve well in his operations role at the interface of science and business.
Joseph S. Solomkin, M.D., Senior Consultant for Surgery and Medicine
Dr. Solomkin is an international leader in scientific and clinical understanding of surgical and post-traumatic infections. He is Professor of Surgery Emeritus at the University of Cincinnati Department of Surgery and founder and Executive Director of the International Surgical Infection Study Group. Dr. Solomkin is regularly involved in guideline projects, including work with the Centers for Disease Control (CDC), Food and Drug Administration (FDA), and World Health Organization (WHO).
BOARD OF DIRECTORS
Michael Flesch, Chairman
Albert Carnesale, Ph.D.
Michael P. Bevilacqua, M.D., Ph.D. (see above)